Oncology Clinical Pathways Spotlight
This week in health care trends, our oncology clinical pathways spotlight includes an expert panel’s discussion of pathways and payment reform and data about the impact of integrated delivery networks (IDNs) on drug selection and oncologist behavior.
The articles below are from our dedicated Oncology Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check out this e-magazine (and others) frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
At the recent Community Oncology Conference, an expert panel tried to solve ““The Pathway Conundrum: How Many Do We Need and How Restrictive?” The panel discussed several pilot programs as well as the role of bundled payments and personalized medicine.
In this article, a physician shares his experiences with payment reform in the fight against cancer: “As part of the 21st Century Oncology network, I have witnessed the powerful effects of payment reform in the private sector. Through a “bundled payment” for all radiation oncology services, my team and I have been uninhibited by inefficient payment structures and have, therefore, been able to efficiently provide a range of integrated services to patients.”
Integrated Delivery Networks and Oncology Care Delivery: Changing the Tide, or Changing the Sign Outside?
As the healthcare market has begun to trend toward mergers, acquisitions, and partnerships between hospitals, clinics, and even health plans, integrated delivery networks have become more common. This detailed report explores the impact of integrated delivery networks (IDNs) on drug selection and oncologist behavior, including specific data in colorful graphs.